

8,430 Dead 354,177 Injuries: European Database of Adverse Drug Reactions for COVID-19 “Vaccines”

By [Brian Shilhavy](#)

Global Research, April 30, 2021

[Health Impact News](#) 29 April 2021

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles **can be read in 51 languages by activating the “Translate Website”** drop down menu on the top banner of our home page (Desktop version).

The European database of suspected drug reaction reports is [EudraVigilance](#), which also tracks reports of injuries and deaths following the experimental COVID-19 “vaccines.”

Here is what [EudraVigilance](#) states about their database:

This website was launched by the [European Medicines Agency](#) in 2012 **to provide public access to reports of suspected side effects** (also known as suspected adverse drug reactions). These reports are submitted electronically to [EudraVigilance](#) by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorisations (licences) for the medicines.

EudraVigilance is a system designed for collecting reports of suspected side effects. These reports are used for evaluating the benefits and risks of medicines during their development and monitoring their safety following their authorisation in the European Economic Area (EEA). EudraVigilance has been in use since December 2001.

This website was launched to comply with the [EudraVigilance Access Policy](#), which was developed to improve public health by supporting the monitoring of the safety of medicines and to increase transparency for stakeholders, including the general public.

The [Management Board of the European Medicines Agency](#) first approved the EudraVigilance Access Policy in December 2010. A revision was adopted by the Board in December 2015 based on the 2010 pharmacovigilance legislation. The policy aims to provide stakeholders such as national medicines regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organisations, with access to reports on suspected side effects.

Transparency is a key guiding principle of the Agency, and is pivotal to building trust and confidence in the regulatory process. By increasing transparency, the Agency is better able to address the growing need among stakeholders, including the general public, for access to information. ([Source](#).)



EudraVigilance - European database of suspected adverse drug reaction reports

The European Medicines Agency publishes these data so that its stakeholders, including the general public, can access information that European regulatory authorities use to review the safety of a medicine or active substance. **Transparency** is a key guiding principle of the Agency.

COVID-19 Vaccine Adverse Drug Reactions
8,430 DEAD
354,177 Injuries Through April 24, 2021
COVID-19 MRNA VACCINE MODERNA (CX-024414)
COVID-19 MRNA VACCINE PFIZER-BIONTECH
COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)
COVID-19 VACCINE JANSSEN (AD26.COV2.S)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EudraVigilance

Their report through April 24, 2021 lists **8,430 deaths and 354,177 injuries** following injections of four experimental COVID-19 shots:

- [COVID-19 MRNA VACCINE MODERNA \(CX-024414\)](#)
- [COVID-19 MRNA VACCINE PFIZER-BIONTECH](#)
- [COVID-19 VACCINE ASTRAZENECA \(CHADOX1 NCOV-19\)](#)
- [COVID-19 VACCINE JANSSEN \(AD26.COV2.S\)](#)

A *Health Impact News* subscriber in Europe ran the reports for each of the four COVID-19 shots we are including here. This subscriber has volunteered to do this, and it is a lot of work to tabulate each reaction with injuries and fatalities, since there is no place on the [EudraVigilance](#) system we have found that tabulates all the results.

Since we have started publishing this, others from Europe have also calculated the numbers and confirmed the totals.

Here is the summary data through April 24, 2021.

Total reactions for the experimental mRNA vaccine **Tozinameran** (code **BNT162b2,Comirnaty**) from **BioNTech/ Pfizer**: **4,524 deaths** and **151,306** injuries to 24/04/2021

- 11,191 Blood and lymphatic system disorders **incl. 40 deaths**
- 7,372 Cardiac disorders **incl. 522 deaths**
- 50 Congenital, familial and genetic disorders **incl. 3 deaths**

- 4,183 Ear and labyrinth disorders **incl. 3 deaths**
- 112 Endocrine disorders
- 4,629 Eye disorders **incl. 6 deaths**
- 33,33 Gastrointestinal disorders **incl. 227 deaths**
- 103,813 General disorders and administration site conditions **incl. 1459 deaths**
- 214 Hepatobiliary disorders **incl. 16 deaths**
- 3,338 Immune system disorders **incl. 20 deaths**
- 10,160 Infections and infestations **incl. 527 deaths**
- 3,950 Injury, poisoning and procedural complications **incl. 89 deaths**
- 7,595 Investigations **incl. 168 deaths**
- 2,564 Metabolism and nutrition disorders **incl. 91 deaths**
- 53,714 Musculoskeletal and connective tissue disorders **incl. 47 deaths**
- 150 Neoplasms benign, malignant and unspecified (incl cysts and polyps) **incl. 7 deaths**
- 65,745 Nervous system disorders **incl. 425 deaths**
- 192 Pregnancy, puerperium and perinatal conditions **incl. 7 deaths**
- 80 Product issues
- 6,008 Psychiatric disorders **incl. 63 deaths**
- 938 Renal and urinary disorders **incl. 66 deaths**
- 994 Reproductive system and breast disorders **incl. 1 death**
- 13,954 Respiratory, thoracic and mediastinal disorders **incl. 523 deaths**
- 16,171 Skin and subcutaneous tissue disorders **incl. 35 deaths**
- 438 Social circumstances **incl. 6 deaths**
- 124 Surgical and medical procedures **incl. 8 deaths**
- 8,220 Vascular disorders **incl. 165 deaths**

Total reactions for the experimental mRNA vaccine mRNA-1273 (CX-024414) from Moderna: 2,283 deaths and 17,625 injuries to 24/04/2021

- 839 Blood and lymphatic system disorders **incl. 16 deaths**
- 1,278 Cardiac disorders **incl. 231 deaths**
- 7 Congenital, familial and genetic disorders **incl. 2 deaths**
- 378 Ear and labyrinth disorders
- 23 Endocrine disorders **incl. 1 death**
- 570 Eye disorders **incl. 3 deaths**
- 3,857 Gastrointestinal disorders **incl. 80 deaths**
- 12,513 General disorders and administration site conditions **incl. 1012 deaths**
- 77 Hepatobiliary disorders **incl. 3 deaths**
- 476 Immune system disorders **incl. 3 deaths**
- 1,449 Infections and infestations **incl. 118 deaths**
- 803 Injury, poisoning and procedural complications **incl. 44 deaths**
- 1,087 Investigations **incl. 60 deaths**
- 515 Metabolism and nutrition disorders **incl. 47 deaths**
- 5,669 Musculoskeletal and connective tissue disorders **incl. 47 deaths**
- 48 Neoplasms benign, malignant and unspecified (incl cysts and polyps) **incl. 8 deaths**
- 7,489 Nervous system disorders **incl. 244 deaths**
- 50 Pregnancy, puerperium and perinatal conditions
- 8 Product issues

- 862 Psychiatric disorders **incl. 31 deaths**
- 299 Renal and urinary disorders **incl. 23 deaths**
- 106 Reproductive system and breast disorders **incl. 1 death**
- 2,198 Respiratory, thoracic and mediastinal disorders **incl. 197 deaths**
- 2,163 Skin and subcutaneous tissue disorders **incl. 19 deaths**
- 162 Social circumstances **incl. 6 deaths**
- 109 Surgical and medical procedures **incl. 13 deaths**
- 1,166 Vascular disorders **incl. 74 deaths**

Total reactions for the experimental vaccine **AZD1222 (CHADOX1 NCOV-19) from Oxford/ AstraZeneca: 1,579 deaths** and **184,833 injuries** to 24/04/2021

- 5,319 Blood and lymphatic system disorders **incl. 64 deaths**
- 7,374 Cardiac disorders **incl. 199 deaths**
- 76 Congenital, familial and genetic disorders **incl. 2 deaths**
- 5,011 Ear and labyrinth disorders
- 155 Endocrine disorders **incl. 2 deaths**
- 7,922 Eye disorders **incl. 5 deaths**
- 56,473 Gastrointestinal disorders **incl. 62 deaths**
- 141,042 General disorders and administration site conditions **incl. 495 deaths**
- 248 Hepatobiliary disorders **incl. 13 deaths**
- 1,837 Immune system disorders **incl. 7 deaths**
- 10,631 Infections and infestations **incl. 99 deaths**
- 4,341 Injury, poisoning and procedural complications **incl. 18 deaths**
- 9,798 Investigations **incl. 21 deaths**
- 6,977 Metabolism and nutrition disorders **incl. 18 deaths**
- 82,522 Musculoskeletal and connective tissue disorders **incl. 16 deaths**
- 144 Neoplasms benign, malignant and unspecified (incl cysts and polyps) **incl. 4 deaths**
- 111,873 Nervous system disorders **incl. 244 deaths**
- 108 Pregnancy, puerperium and perinatal conditions
- 52 Product issues
- 9,514 Psychiatric disorders **incl. 12 deaths**
- 1,745 Renal and urinary disorders **incl. 11 deaths**
- 2,076 Reproductive system and breast disorders
- 15,824 Respiratory, thoracic and mediastinal disorders **incl. 171 deaths**
- 23,168 Skin and subcutaneous tissue disorders **incl. 10 deaths**
- 364 Social circumstances **incl. 3 deaths**
- 383 Surgical and medical procedures **incl. 12 deaths**
- 8,706 Vascular disorders **incl. 91 deaths**

Total reactions for the experimental **COVID-19 vaccine JANSSEN (AD26.COV2.S) from Johnson & Johnson: 44 deaths** and **413 injuries** to 24/04/2021

- 11 Blood and lymphatic system disorders
- 45 Cardiac disorders **incl. 10 deaths**
- 1 Congenital, familial and genetic disorder
- 20 Ear and labyrinth disorders
- 1 Endocrine disorder

- 20 Eye disorders
- 109 Gastrointestinal disorders **incl. 1 death**
- 235 General disorders and administration site conditions **incl. 14 deaths**
- 3 Hepatobiliary disorders
- 18 Immune system disorders
- 44 Infections and infestations **incl. 2 deaths**
- 34 Injury, poisoning and procedural complications **incl. 1 death**
- 61 Investigations
- 19 Metabolism and nutrition disorders **incl. 1 death**
- 95 Musculoskeletal and connective tissue disorders **incl. 1 death**
- 232 Nervous system disorders **incl. 3 deaths**
- 3 Product issues
- 45 Psychiatric disorders
- 11 Renal and urinary disorders
- 5 Reproductive system and breast disorders
- 80 Respiratory, thoracic and mediastinal disorders **incl. 3 deaths**
- 50 Skin and subcutaneous tissue disorders
- 5 Social circumstances
- 3 Surgical and medical procedures
- 96 Vascular disorders **incl. 8 deaths**

This is public information funded by the European Medicines Agency (EMA), and anyone can use the [EudraVigilance](#) system and verify this data.

[Denmark](#) and [Norway](#) have completely suspended use of the AstraZeneca experimental COVID-19 shots.

A statement issued by the [Norwegian Institute of Public Health](#) stated that the AstraZeneca COVID “vaccine” is more dangerous than COVID itself, especially for young people.

The EMA continues to recommend it. They did, however, add a safety warning to the J&J shots, due to fatal blood clots. ([Source.](#))

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is [Health Impact News](#)
 Copyright © [Brian Shilhavy](#), [Health Impact News](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Brian Shilhavy](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca